Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review269
Editorial Board178
Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming144
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer119
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives99
Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors96
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer95
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis94
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in83
Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis82
The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology82
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer79
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty75
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis71
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches63
Proton therapy in breast cancer: bridging medical and radiation oncology60
Editorial Board59
De-escalation strategies with targeted therapies in non-small cell lung cancer57
If it’s a target, it’s a pan-cancer target: Tissue is not the issue57
Progress toward personalized management of stage II/III triple negative breast cancer56
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications55
Revisiting patient preference in resectable and irradiable stage III NSCLC in the immunotherapy era54
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma54
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment54
Emerging antibody-based therapies for the treatment of acute myeloid leukemia53
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.53
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?53
Optimizing care in early phase cancer trials: The role of palliative care53
Editorial Board52
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era52
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?51
Editorial Board50
Uncertainties and controversies in axillary management of patients with breast cancer50
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC49
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation47
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?47
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck47
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment47
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials47
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy46
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes46
Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation46
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier44
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations44
Extracellular vesicles and the “six Rs” in radiotherapy42
Editorial Board42
Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working group (TARPSWG)39
Overview of BH3 mimetics in ovarian cancer39
Corrigendum to “The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management”. [Cancer Treat. Rev. 139 (2025) 102998]39
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design38
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review37
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis36
The immunogram of inflammatory breast cancer36
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis35
The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions35
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside34
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada34
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review34
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma33
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma33
Long-term surveillance recommendations for young adult cancer survivors32
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers32
Clinical efficacy and immunological aspects of neoadjuvant and perioperative therapy in resectable head and neck carcinoma32
Expanding the therapeutic Frontier: Liver transplantation for unresectable colorectal liver metastases32
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)32
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies31
Editorial Board31
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review31
Assessing lung function in women treated for breast cancer with radiotherapy. A comprehensive systematic review and meta-analysis30
Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials30
Agnostic drug development revisited30
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer30
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review30
Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review30
Systematic review of the CUP trials characteristics and perspectives for next-generation studies30
Bone complications of cancer treatment29
Immunocytokines in cancer treatment: A systematic review28
Malignant ascites: Current therapy options and treatment prospects28
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer28
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life28
Editorial Board28
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers27
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis27
Editorial Board27
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?27
Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review26
Genomic distinctions in adolescent and young adult cancer: A comprehensive review26
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review26
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review26
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?26
Corrigendum to “T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis”. [Cancer Treat Rev. 139 (2025) 102991. doi: 10.1016/j.ctrv.2025.102991]26
Prognostic role of postoperative circulating tumor DNA in metastatic colorectal cancer treated with curative intent: A systematic review and meta-analysis25
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review25
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes25
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review25
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification25
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges25
Local control strategies for management of NSCLC with oligoprogressive disease25
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis24
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project24
Engineering strategies to optimise adoptive cell therapy in ovarian cancer24
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie24
Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies24
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives24
Management of infections in the outpatient care of patients with cancer23
Evolving immunotherapeutic solutions for triple-negative breast carcinoma23
Review: Targeting EZH2 in neuroblastoma23
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer23
Pharmacotherapy for leptomeningeal disease in breast cancer23
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis23
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]23
Strategies for improving detection of circulating tumor DNA using next generation sequencing23
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis22
Editorial Board22
Diagnostic utility of urinary cell-free DNA in non-urothelial cancer: a systematic review, meta-analysis, & network meta-analysis22
Editorial Board22
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies22
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications21
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review21
Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy21
Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non–small cell lung cancer21
Ex vivo drug screening on patient-derived tumor material to advance functional precision in oncology: an overview on current approaches and unresolved challenges21
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives20
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review20
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression20
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases20
Editorial Board20
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment20
0.15614914894104